<DOC>
	<DOC>NCT02941354</DOC>
	<brief_summary>This trial is conducted globally. The aim of this trial is evaluating the pharmacokinetics (the exposure of the trial drug in the body) of NovoEight® (turoctocog alfa) in relation to BMI (body mass index) in subjects with haemophilia A.</brief_summary>
	<brief_title>Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male, age at least 18 years at the time of signing informed consent History of more than 75 exposure days to any factor VIII products Subjects with the diagnosis of congenital haemophilia A with factor VIII activity below 1%, based on medical records Known history of factor VIII inhibitors Inhibitors to factor VIII (above or equal to 0.6 BU (Bethesda units)) at screening measured by the Nijmegen modified Bethesda method Known congenital or acquired coagulation disorders other than haemophilia A Previous participation in pharmacokinetic sessions with turoctocog alfa in another trial</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>